ARGENX SE-ADR (ARGX) Receives Average Recommendation of “Strong Buy” from Brokerages
ARGENX SE-ADR (NASDAQ:ARGX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Brokers have set a 12 month consensus price target of $36.33 for the company, according to Zacks. Zacks has also given ARGENX SE-ADR an industry rank of 110 out of 265 based on the ratings given to its competitors.
A number of analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $41.00 price objective (up previously from $26.00) on shares of ARGENX SE-ADR in a research report on Thursday, November 16th. They noted that the move was a valuation call. Zacks Investment Research raised ARGENX SE-ADR from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Cowen and Company reissued a “buy” rating on shares of ARGENX SE-ADR in a research report on Thursday, August 24th.
ARGENX SE-ADR (NASDAQ ARGX) traded up $0.42 during trading on Friday, hitting $25.00. The stock had a trading volume of 121,700 shares, compared to its average volume of 30,301. ARGENX SE-ADR has a 52-week low of $17.33 and a 52-week high of $27.25.
A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC acquired a new stake in ARGENX SE-ADR during the 2nd quarter worth about $15,990,000. VHCP Management II LLC acquired a new stake in ARGENX SE-ADR during the 2nd quarter worth about $13,615,000. Pictet Asset Management Ltd. acquired a new stake in ARGENX SE-ADR during the 3rd quarter worth about $11,812,000. Federated Investors Inc. PA acquired a new stake in ARGENX SE-ADR during the 2nd quarter worth about $9,545,000. Finally, Franklin Resources Inc. acquired a new stake in ARGENX SE-ADR during the 2nd quarter worth about $7,424,000. 24.68% of the stock is owned by institutional investors.
About ARGENX SE-ADR
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related stocks with our FREE daily email newsletter.